Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.70 |
| ▸ | PIM3 | Q86V86 | 7/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11908015 | 0.87 | PIM1 (0.70) | PIM1PIM3PIM2ATRPRKCA | |
| SCHEMBL11907023 | 0.86 | IRAK4 (0.59) | PIM1PIM3PIM2ALOX15TSHR | |
| SCHEMBL11907344 | 0.85 | PIM1 (0.78) | PIM1PIM3PIM2ATRPRKCA | |
| SCHEMBL11907589 | 0.85 | PIM1 (0.67) | PIM1PIM3PIM2TSHRMAPK1 | |
| SCHEMBL11907083 | 0.84 | PIM1 (0.66) | PIM1PIM3PIM2TSHRL3MBTL1 | |
| SCHEMBL11906947 | 0.83 | PIM1 (0.64) | PIM1PIM3PIM2PRKCAGSK3B | |
| SCHEMBL11984469 | 0.83 | PIM1 (0.64) | PIM1PIM3PIM2TSHRATR | |
| SCHEMBL11906979 | 0.82 | PIM1 (1.00) | PIM1PIM3PIM2ATRPRKCA | |
| SCHEMBL11909771 | 0.81 | PIM1 (0.68) | PIM1PIM3PIM2ATRPRKCA | |
| SCHEMBL11909287 | 0.81 | PIM2 (0.72) | PIM1PIM3PIM2ATRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.